Caisse Des Depots ET Consignations Boosts Stock Position in Kenvue Inc. $KVUE

Caisse Des Depots ET Consignations raised its stake in Kenvue Inc. (NYSE:KVUE) by 31.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 318,100 shares of the company’s stock after purchasing an additional 76,015 shares during the period. Caisse Des Depots ET Consignations’ holdings in Kenvue were worth $5,487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Arrowstreet Capital Limited Partnership purchased a new position in Kenvue in the second quarter valued at about $6,528,000. Jump Financial LLC grew its stake in Kenvue by 210.6% in the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock valued at $1,147,000 after purchasing an additional 37,170 shares during the last quarter. AXA S.A. grew its stake in Kenvue by 21.1% in the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock valued at $1,023,000 after purchasing an additional 8,524 shares during the last quarter. NewEdge Advisors LLC grew its stake in Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after purchasing an additional 66,930 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Kenvue by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock valued at $39,217,000 after purchasing an additional 10,885 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $17.44 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The company has a market cap of $33.48 billion, a PE ratio of 22.65, a P/E/G ratio of 3.98 and a beta of 0.61. The business has a 50-day simple moving average of $17.72 and a two-hundred day simple moving average of $17.17. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The company’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the company earned $0.26 earnings per share. As a group, equities analysts expect that Kenvue Inc. will post 1.1 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be issued a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. Kenvue’s payout ratio is 107.79%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several analyst reports. Citigroup cut their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Canaccord Genuity Group lifted their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. UBS Group cut their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Finally, Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.